

# Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.9	101.2	(43.6-199.3)	Male	6	6.0	100.6	(36.7-218.9)
Female	4	2.8	nc	(nc-nc)	Female	6	4.8	125.4	(45.8-273.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.2	135.5	(54.3-279.2)
Female	36	35.2	102.3	(71.6-141.6)	Female	7	4.0	176.9	(70.9-364.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	10.1	109.4	(54.5-195.8)	Female	4	3.1	nc	(nc-nc)
Female	12	9.2	130.9	(67.6-228.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	2	2.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	1	0.8	nc	(nc-nc)	Female	46	37.1	123.9	(90.7-165.3)
Female	3	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	8	5.1	157.9	(68.0-311.1)	Female	1	1.1	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	2	1.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	4	3.2	nc	(nc-nc)	Female	5	2.3	217.7	(70.2-508.0)
Female	0	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	3	3.0	nc	(nc-nc)	Male	6	8.2	73.3	(26.8-159.6)
Female	0	0.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	19	15.2	125.0	(75.2-195.2)	Female	139	122.1	113.9	(95.7-134.4)
Female	15	15.2	98.8	(55.3-163.0)	Female				
					116				
					114.5				
					101.3				
					(83.7-121.5)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	22.5	79.8	(47.3-126.2)	Male	13	15.2	85.5	(45.5-146.2)
Female	8	8.6	92.8	(39.9-182.8)	Female	4	11.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.6	130.6	(47.7-284.3)	Male	6	3.9	152.8	(55.8-332.6)
Female	3	3.7	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	19	13.4	141.6	(85.2-221.1)
Female	75	82.6	90.8	(71.4-113.8)	Female	12	11.1	108.5	(56.0-189.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.0	nc	(nc-nc)	Male	14	9.6	145.2	(79.3-243.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	26	26.8	97.0	(63.4-142.2)	Female	6	7.8	77.2	(28.2-168.1)
Female	29	28.5	101.7	(68.1-146.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	7.3	95.4	(38.2-196.6)
Male	9	5.9	151.6	(69.2-287.8)	Female	11	8.6	128.3	(63.9-229.5)
Female	2	1.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	90	82.2	109.4	(88.0-134.5)
Male	1	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	6	5.3	113.3	(41.4-246.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	3.5	143.6	(46.3-335.2)
Male	9	12.2	73.7	(33.7-140.0)	<b><u>Testis</u></b>				
Female	6	7.0	86.0	(31.4-187.3)	Male	5	3.7	134.2	(43.2-313.2)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	11	14.7	75.1	(37.4-134.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	8.7	nc	(nc-nc)	Female	22	18.6	118.4	(74.2-179.2)
Female	7	6.6	105.7	(42.4-217.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	323	304.1	106.2	(94.9-118.4)
Male	7	7.0	99.4	(39.8-204.7)	Female	279	298.0	93.6	(83.0-105.3)
Female	1	2.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	51	40.1	127.2	(94.7-167.2)					
Female	40	43.0	93.0	(66.4-126.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.4	80.8	(29.5-175.9)	Male	4	5.4	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	5	4.2	118.0	(38.0-275.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.8	166.0	(71.5-327.1)
Female	37	31.3	118.2	(83.2-162.9)	Female	7	3.5	198.4	(79.5-408.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	9.4	95.7	(43.7-181.6)	Female	1	2.8	nc	(nc-nc)
Female	6	8.2	72.8	(26.6-158.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	4	2.1	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	39	30.8	126.5	(90.0-173.0)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	7	4.6	150.7	(60.4-310.5)	Male	1	1.8	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	5	3.0	165.4	(53.3-385.9)	Male	2	2.1	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	8	6.3	127.7	(55.0-251.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.6	nc	(nc-nc)	Female	5	7.1	70.5	(22.7-164.5)
Female	0	0.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	8	13.9	57.4	(24.7-113.1)	Male	107	109.0	98.2	(80.5-118.7)
Female	21	13.5	155.5	(96.2-237.8)	Female	122	102.0	119.6	(99.3-142.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	8	6.6	121.0	(52.1-238.4)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	13	7.2	181.1	(96.3-309.7)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	0.6	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	31	23.8	130.3	(88.5-185.0)
Male	0	0.6	nc	(nc-nc)	Female	28	22.0	127.2	(84.5-183.9)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	0	3.1	nc	(nc-nc)					
Female	7	3.0	234.5	(93.9-483.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	45	41.9	107.5	(78.4-143.9)	Male	37	26.7	138.8	(97.7-191.3)
Female	13	14.0	92.9	(49.4-158.8)	Female	27	19.3	139.7	(92.0-203.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	7.3	163.9	(84.6-286.4)	Male	5	7.2	69.0	(22.2-161.0)
Female	5	6.0	83.6	(26.9-195.0)	Female	6	5.4	112.1	(40.9-243.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	25	23.4	107.0	(69.2-158.0)
Female	122	142.9	85.4	(70.9-101.9)	Female	17	18.2	93.3	(54.3-149.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.1	118.2	(43.2-257.3)	Male	18	17.2	104.8	(62.1-165.6)
<b><u>Colon / Rectum</u></b>					Female	18	7.3	246.2	(145.8-389.1)
Male	49	48.5	101.0	(74.7-133.5)	<b><u>Ovary</u></b>				
Female	39	45.5	85.7	(60.9-117.1)	Female	8	13.2	60.5	(26.0-119.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	11.3	88.9	(42.5-163.5)	Male	12	13.6	88.0	(45.4-153.6)
Female	3	2.9	nc	(nc-nc)	Female	15	13.8	108.7	(60.8-179.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	154	164.2	93.8	(79.5-109.8)
Female	4	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	9.7	102.6	(49.1-188.8)
Male	19	22.1	85.9	(51.7-134.2)	Female	6	5.4	110.1	(40.2-239.6)
Female	18	11.9	151.7	(89.9-239.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	3.8	186.3	(74.6-383.8)
Male	7	6.5	107.5	(43.1-221.6)	<b><u>Thyroid</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	6	8.6	69.7	(25.5-151.8)
<b><u>Leukemia</u></b>					Female	27	24.4	110.5	(72.8-160.8)
Male	17	15.0	113.6	(66.1-181.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	10.5	47.6	(15.3-111.0)	Female	29	33.2	87.2	(58.4-125.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	12.8	78.0	(37.3-143.4)	Male	578	562.7	102.7	(94.5-111.5)
Female	7	4.0	174.6	(69.9-359.8)	Female	504	499.7	100.9	(92.3-110.1)
<b><u>Lung and Bronchus</u></b>									
Male	85	77.0	110.4	(88.2-136.6)					
Female	91	72.7	125.2	(100.8-153.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	4.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	1.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	5.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	0.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	9	17.9	50.1	(22.9-95.2)
Female	0	0.1	nc	(nc-nc)	Female	9	15.0	60.1	(27.4-114.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	9	17.9	50.1	(22.9-95.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	9	15.0	60.1	(27.4-114.1)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	9	17.9	50.1	(22.9-95.2)
Female	0	2.0	nc	(nc-nc)	Female	9	15.0	60.1	(27.4-114.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	13.5	103.3	(56.4-173.4)	Male	5	10.0	49.8	(16.0-116.2)
Female	4	5.5	nc	(nc-nc)	Female	12	9.2	130.6	(67.4-228.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.2	187.9	(68.6-409.0)	Male	4	2.5	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	8.7	92.3	(39.7-181.8)
Female	78	64.8	120.3	(95.1-150.2)	Female	8	7.7	104.1	(44.8-205.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.7	nc	(nc-nc)	Male	9	6.7	133.8	(61.1-254.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	13	16.6	78.2	(41.6-133.7)	Female	8	5.8	136.9	(58.9-269.7)
Female	24	18.3	131.0	(83.9-194.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	4.6	173.2	(74.6-341.3)
Male	11	4.0	275.2	(137.2-492.5)	Female	5	5.4	92.5	(29.8-215.9)
Female	0	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	65	58.6	110.9	(85.6-141.3)
Male	0	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	11	8.4	130.4	(65.0-233.3)	Female	2	2.2	nc	(nc-nc)
Female	10	5.2	193.8	(92.8-356.3)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					Male	4	2.6	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	18	14.6	123.1	(72.9-194.6)
<b><u>Leukemia</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	5.5	200.3	(99.9-358.5)	Male	219	201.3	108.8	(94.8-124.2)
Female	6	4.6	129.6	(47.3-282.1)	Female	238	218.3	109.0	(95.6-123.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	3	4.8	nc	(nc-nc)					
Female	0	1.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	27	25.9	104.4	(68.8-151.9)					
Female	33	29.4	112.4	(77.3-157.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.5	76.8	(24.7-179.2)	Male	2	4.6	nc	(nc-nc)
Female	5	2.2	223.5	(72.0-521.5)	Female	1	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	25	26.0	96.1	(62.2-141.9)	Female	3	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	8.0	75.3	(27.5-164.0)	Female	4	2.3	nc	(nc-nc)
Female	6	7.3	82.3	(30.1-179.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.2	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	25	27.6	90.7	(58.7-133.8)
Male	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.9	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	5.0	100.8	(32.5-235.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	2.5	nc	(nc-nc)	Female	9	6.0	149.2	(68.1-283.3)
Female	0	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	82	93.8	87.4	(69.5-108.5)
Male	2	2.2	nc	(nc-nc)	Female	76	87.1	87.2	(68.7-109.2)
Female	0	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	12	12.5	95.7	(49.4-167.2)					
Female	9	12.1	74.6	(34.0-141.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	10	6.5	153.0	(73.2-281.3)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	10	7.1	141.2	(67.6-259.7)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	24	23.0	104.4	(66.9-155.4)
Male	0	0.6	nc	(nc-nc)	Female	25	21.4	117.1	(75.8-172.9)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	3.0	nc	(nc-nc)					
Female	3	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	12.1	82.8	(39.7-152.4)	Male	15	7.3	206.1	(115.3-340.0)
Female	7	3.9	180.6	(72.3-372.0)	Female	8	4.9	161.7	(69.6-318.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.4	94.4	(34.5-205.4)
Female	41	36.2	113.1	(81.2-153.5)	Female	3	4.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	13.5	111.3	(62.2-183.6)	Female	1	3.4	nc	(nc-nc)
Female	17	12.7	133.4	(77.6-213.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	3.9	nc	(nc-nc)
Male	6	3.1	192.4	(70.2-418.7)	Female	2	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	37	45.0	82.3	(57.9-113.4)
Male	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.6	nc	(nc-nc)
Male	6	5.9	102.4	(37.4-222.8)	<b><u>Testis</u></b>				
Female	2	3.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	8	5.8	138.2	(59.5-272.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	4.1	nc	(nc-nc)	Female	9	8.4	107.0	(48.8-203.2)
Female	3	2.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	137	155.2	88.2	(74.1-104.3)
Male	3	3.5	nc	(nc-nc)	Female	135	131.0	103.1	(86.4-122.0)
Female	1	1.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	21.7	101.3	(63.5-153.4)					
Female	20	19.2	103.9	(63.5-160.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	21.1	99.4	(61.5-151.9)	Male	12	13.5	88.6	(45.7-154.7)
Female	7	8.9	79.0	(31.7-162.8)	Female	7	11.6	60.2	(24.1-124.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.9	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	7	3.6	193.5	(77.5-398.7)	Female	1	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	8	12.0	66.5	(28.6-131.1)
Female	93	82.4	112.8	(91.1-138.3)	Female	14	11.2	124.9	(68.2-209.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	2.9	170.3	(54.9-397.3)	Male	5	8.6	58.2	(18.7-135.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	22	24.7	89.2	(55.9-135.0)	Female	8	7.9	101.8	(43.8-200.5)
Female	28	29.5	94.8	(63.0-137.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	6.8	103.0	(41.3-212.2)
Male	5	5.5	90.5	(29.2-211.2)	Female	9	8.8	101.7	(46.4-193.1)
Female	0	1.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	66	78.7	83.9	(64.9-106.7)
Male	2	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	3.6	137.8	(44.4-321.5)
Male	9	10.9	82.4	(37.6-156.4)	<b><u>Testis</u></b>				
Female	5	6.9	72.0	(23.2-168.1)	Male	0	2.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	3.2	157.1	(50.6-366.7)	Male	2	4.5	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	7	14.1	49.8	(20.0-102.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	7.9	nc	(nc-nc)	Female	18	18.7	96.1	(56.9-151.9)
Female	5	6.6	75.4	(24.3-175.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	251	280.7	89.4	(78.7-101.2)
Male	4	6.4	nc	(nc-nc)	Female	280	299.8	93.4	(82.8-105.0)
Female	5	2.4	204.9	(66.0-478.1)					
<b><u>Lung and Bronchus</u></b>									
Male	47	37.6	125.0	(91.8-166.2)					
Female	35	43.0	81.4	(56.7-113.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	9.2	97.8	(44.6-185.6)	Male	5	6.7	75.1	(24.2-175.3)
Female	2	2.9	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	5	1.6	310.5	(100.1-724.5)	Female	3	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
Female	43	38.1	112.8	(81.6-151.9)	Female	1	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	5	4.7	106.5	(34.3-248.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	11.8	101.4	(52.3-177.2)	Female	5	3.3	150.2	(48.4-350.5)
Female	6	9.8	61.4	(22.4-133.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	3.1	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	39	38.9	100.2	(71.2-136.9)
Male	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.1	nc	(nc-nc)
Male	2	5.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	9	7.9	114.6	(52.3-217.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	3.8	nc	(nc-nc)	Female	8	8.5	94.5	(40.7-186.3)
Female	2	2.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	126	135.6	92.9	(77.4-110.7)
Male	5	3.3	149.4	(48.2-348.7)	Female	118	122.0	96.7	(80.1-115.9)
Female	1	0.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	13	17.0	76.4	(40.7-130.7)					
Female	12	15.3	78.2	(40.3-136.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.8	103.1	(37.7-224.5)	Male	3	4.2	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	5	3.7	136.9	(44.1-319.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	30	27.1	110.8	(74.7-158.1)	Female	6	3.2	186.5	(68.1-405.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	7.2	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	7	7.8	90.0	(36.1-185.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	1.9	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	23	24.2	95.0	(60.2-142.5)
Male	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.9	nc	(nc-nc)
Male	5	3.5	141.9	(45.7-331.0)	<b><u>Testis</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	7	5.0	138.6	(55.5-285.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	2.4	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	84	84.8	99.1	(79.0-122.7)
Male	0	2.1	nc	(nc-nc)	Female	97	90.9	106.7	(86.5-130.2)
Female	0	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	13	10.9	119.0	(63.3-203.6)					
Female	15	12.6	118.9	(66.5-196.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	7.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	5	2.9	173.7	(56.0-405.5)	Female	6	3.6	167.8	(61.3-365.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.7	187.6	(75.1-386.5)
Female	29	25.9	112.2	(75.1-161.1)	Female	4	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	7.9	139.7	(69.6-249.9)	Female	5	2.5	202.3	(65.2-472.1)
Female	10	9.6	104.6	(50.1-192.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	2.3	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	Female	5	2.9	173.8	(56.0-405.6)
Female	1	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	24	25.4	94.4	(60.5-140.5)
Male	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.2	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	2.4	nc	(nc-nc)	Female	5	5.9	85.3	(27.5-199.0)
Female	2	2.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	82	89.9	91.2	(72.6-113.3)
Male	0	2.1	nc	(nc-nc)	Female	109	94.9	114.9	(94.3-138.6)
Female	0	0.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	12.5	47.8	(17.5-104.1)					
Female	14	13.9	100.6	(54.9-168.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.2	124.6	(56.9-236.6)	Male	6	5.2	114.6	(41.8-249.4)
Female	1	3.0	nc	(nc-nc)	Female	5	4.5	111.4	(35.9-260.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.5	176.5	(76.0-347.7)
Female	28	33.1	84.6	(56.2-122.3)	Female	6	4.0	149.8	(54.7-326.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	9.0	77.9	(31.2-160.5)	Female	5	3.0	167.1	(53.9-390.0)
Female	12	9.5	125.7	(64.9-219.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	2	2.2	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	36	34.3	105.0	(73.5-145.4)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	9	4.5	201.0	(91.7-381.5)	Male	2	1.8	nc	(nc-nc)
Female	0	2.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	2.8	nc	(nc-nc)	Male	6	1.9	310.0	(113.2-674.8)
Female	4	2.3	nc	(nc-nc)	Female	10	6.1	163.1	(78.1-300.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	2.6	nc	(nc-nc)	Female	4	7.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	20	14.1	141.7	(86.5-218.9)	Male	127	110.0	115.5	(96.3-137.4)
Female	21	15.9	131.9	(81.6-201.7)	Female	115	112.2	102.5	(84.6-123.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	8.2	159.2	(84.7-272.3)	Male	12	5.6	215.4	(111.2-376.3)
Female	0	2.5	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	1.7	356.3	(130.1-775.6)	Male	5	1.4	348.9	(112.5-814.3)
Female	3	1.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.0	180.9	(82.5-343.4)
Female	36	30.6	117.8	(82.5-163.1)	Female	3	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	14	10.1	138.8	(75.8-232.9)	Female	8	2.7	292.9	(126.1-577.2)
Female	5	8.4	59.3	(19.1-138.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	2.7	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	27	31.8	84.9	(55.9-123.5)
Male	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.0	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	4	2.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	8	6.0	132.5	(57.1-261.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	3.3	244.7	(105.4-482.3)	Female	9	6.9	129.5	(59.1-245.9)
Female	1	2.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	135	113.8	118.6	(99.5-140.4)
Male	3	2.6	nc	(nc-nc)	Female	104	101.5	102.5	(83.7-124.2)
Female	0	0.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	13	14.6	88.9	(47.3-152.0)					
Female	11	13.7	80.4	(40.1-143.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.5	82.3	(33.0-169.7)	Male	4	5.2	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	5	3.3	152.5	(49.1-355.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.6	109.1	(35.2-254.7)
Female	32	24.6	129.9	(88.8-183.4)	Female	2	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	9.6	72.9	(29.2-150.3)	Female	2	2.3	nc	(nc-nc)
Female	4	7.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	2.7	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	27	32.5	83.1	(54.8-120.9)
Male	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	0.9	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	4	2.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	7	4.2	166.6	(66.8-343.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.0	nc	(nc-nc)	Female	6	5.7	104.8	(38.3-228.2)
Female	0	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	92	111.3	82.7	(66.6-101.4)
Male	2	2.4	nc	(nc-nc)	Female	84	84.8	99.0	(79.0-122.6)
Female	0	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	14	15.5	90.3	(49.3-151.6)					
Female	10	12.0	83.2	(39.8-153.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	3.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	1.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	4	3.6	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	13	12.9	100.6	(53.5-172.1)
Male	0	0.3	nc	(nc-nc)	Female	4	13.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	0	1.8	nc	(nc-nc)					
Female	0	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	13.8	115.8	(66.2-188.1)	Male	12	9.5	125.9	(65.0-219.9)
Female	4	5.0	nc	(nc-nc)	Female	10	7.8	128.9	(61.7-237.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.9	170.7	(55.0-398.5)	Male	3	2.5	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	12	8.5	141.9	(73.3-248.0)
Female	64	57.8	110.7	(85.3-141.4)	Female	10	6.9	145.6	(69.7-267.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	2	6.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	16.6	90.2	(50.4-148.8)	Female	8	5.2	154.4	(66.5-304.2)
Female	25	16.4	152.0	(98.3-224.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	4.5	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	Female	7	4.9	142.3	(57.0-293.2)
Female	2	1.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	66	55.6	118.7	(91.8-151.0)
Male	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	5	3.3	151.8	(48.9-354.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.9	nc	(nc-nc)
Male	10	8.0	125.0	(59.8-229.9)	<b><u>Testis</u></b>				
Female	5	4.6	108.2	(34.9-252.4)	Male	1	1.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	7	3.4	204.9	(82.1-422.2)
Female	2	0.7	nc	(nc-nc)	Female	16	10.7	149.6	(85.4-242.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	5.4	93.4	(30.1-218.0)	Female	14	13.3	105.6	(57.7-177.2)
Female	5	4.0	123.5	(39.8-288.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	206	194.9	105.7	(91.7-121.1)
Male	4	4.6	nc	(nc-nc)	Female	220	193.9	113.4	(98.9-129.5)
Female	1	1.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	20	25.9	77.2	(47.1-119.2)					
Female	26	27.0	96.2	(62.8-141.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	9.4	128.1	(66.1-223.8)	Male	4	6.8	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	5	5.2	96.3	(31.0-224.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	5.9	nc	(nc-nc)
Female	48	38.1	126.1	(93.0-167.2)	Female	9	4.3	209.0	(95.4-396.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	20	11.6	172.9	(105.6-267.0)	Female	4	3.4	nc	(nc-nc)
Female	12	9.9	120.9	(62.4-211.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	3.2	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	54	41.2	131.2	(98.6-171.2)
Male	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.1	nc	(nc-nc)
Male	8	5.8	138.7	(59.7-273.4)	<b><u>Testis</u></b>				
Female	5	3.0	169.1	(54.5-394.5)	Male	3	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	16	7.6	209.4	(119.6-340.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	3.7	164.2	(60.0-357.5)	Female	18	8.8	204.5	(121.1-323.2)
Female	3	2.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	156	138.6	112.5	(95.6-131.6)
Male	2	3.3	nc	(nc-nc)	Female	150	124.3	120.6	(102.1-141.6)
Female	2	0.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	24	18.2	132.0	(84.5-196.4)					
Female	10	16.6	60.4	(28.9-111.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	3.4	176.7	(64.5-384.6)	Male	1	2.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	14	11.1	126.6	(69.2-212.5)	Female	1	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	3.9	155.0	(56.6-337.5)	Female	0	1.0	nc	(nc-nc)
Female	5	3.3	149.8	(48.3-349.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	1.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	11	12.3	89.2	(44.5-159.6)
Male	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.3	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	41	44.3	92.6	(66.4-125.6)
Male	1	1.0	nc	(nc-nc)	Female	39	38.0	102.5	(72.9-140.2)
Female	0	0.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	5	5.9	85.0	(27.4-198.4)					
Female	8	5.3	150.0	(64.6-295.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.4	94.4	(37.8-194.5)	Male	9	5.3	169.4	(77.3-321.5)
Female	0	1.7	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.6	107.7	(34.7-251.3)
Female	21	22.4	93.6	(57.9-143.0)	Female	4	2.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	9.3	75.1	(30.1-154.7)	Female	3	2.0	nc	(nc-nc)
Female	9	5.5	163.9	(74.8-311.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	4	2.2	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	1	0.6	nc	(nc-nc)	Female	29	32.0	90.7	(60.8-130.3)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	3	4.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	1.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	3	2.9	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	2	2.7	nc	(nc-nc)	Male	8	5.3	151.3	(65.1-298.1)
Female	0	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	4	13.9	nc	(nc-nc)	Female	89	108.7	81.9	(65.7-100.7)
Female	2	9.2	nc	(nc-nc)	Female	65	70.7	91.9	(70.9-117.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	46	25.9	177.3	(129.8-236.5)	Male	25	14.6	171.6	(111.0-253.4)
Female	9	9.4	95.4	(43.5-181.1)	Female	27	10.6	255.4	(168.2-371.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	13	12.8	101.7	(54.1-174.0)
Female	106	79.3	133.7	(109.5-161.7)	Female	12	11.4	104.9	(54.2-183.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.4	nc	(nc-nc)	Male	6	8.4	71.2	(26.0-154.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	20	27.6	72.5	(44.3-112.0)	Female	11	7.6	144.4	(72.0-258.4)
Female	37	30.3	122.2	(86.1-168.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	8.1	61.7	(19.9-144.0)
Male	4	6.2	nc	(nc-nc)	Female	9	9.4	95.6	(43.6-181.5)
Female	2	2.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	115	88.3	130.3	(107.5-156.3)
Male	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	3.7	nc	(nc-nc)
Male	8	11.6	69.1	(29.7-136.1)	<b><u>Testis</u></b>				
Female	9	7.1	126.5	(57.7-240.2)	Male	2	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	0	10.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	8.5	94.0	(40.5-185.3)	Female	16	18.4	86.9	(49.7-141.2)
Female	2	6.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	350	313.5	111.6	(100.2-124.0)
Male	5	6.6	75.4	(24.3-175.9)	Female	322	298.1	108.0	(96.5-120.5)
Female	1	2.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	46	46.4	99.2	(72.6-132.3)					
Female	34	47.4	71.7	(49.7-100.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.0	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	19	16.6	114.1	(68.7-178.3)	Female	0	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	4.9	164.0	(70.6-323.1)	Female	3	1.5	nc	(nc-nc)
Female	8	5.1	155.4	(66.9-306.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	20	18.9	105.9	(64.7-163.6)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.4	nc	(nc-nc)	Female	5	3.9	128.2	(41.3-299.2)
Female	1	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	8	7.9	100.9	(43.5-198.9)
Female	0	0.5	nc	(nc-nc)	Female	4	8.4	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	62	57.8	107.3	(82.2-137.5)	Male	36	39.4	91.3	(63.9-126.4)
Female	22	22.7	96.8	(60.6-146.6)	Female	34	34.0	99.9	(69.2-139.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	17	12.1	140.4	(81.7-224.7)	Male	8	10.1	79.5	(34.2-156.6)
Female	9	10.7	84.0	(38.3-159.4)	Female	8	8.7	92.2	(39.7-181.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	36	34.7	103.8	(72.7-143.7)
Female	220	237.7	92.6	(80.7-105.6)	Female	31	30.2	102.5	(69.6-145.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	9.4	63.9	(23.3-139.0)	Male	33	25.2	130.8	(90.0-183.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	86	68.9	124.9	(99.9-154.2)	Female	23	22.0	104.4	(66.2-156.7)
Female	74	75.7	97.8	(76.8-122.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	26	19.0	137.0	(89.5-200.7)
Male	15	15.6	96.1	(53.8-158.6)	Female	26	22.5	115.5	(75.4-169.2)
Female	5	4.7	105.8	(34.1-246.9)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	207	222.3	93.1	(80.9-106.7)
Male	4	5.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	4.7	nc	(nc-nc)	Male	14	13.7	102.5	(56.0-172.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	7	9.1	76.7	(30.7-158.0)
Male	29	32.1	90.4	(60.5-129.8)	<b><u>Testis</u></b>				
Female	22	19.5	112.8	(70.7-170.8)	Male	10	9.4	106.1	(50.8-195.2)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	9.0	77.9	(31.2-160.4)	Male	11	14.1	78.2	(39.0-139.9)
Female	5	2.8	176.7	(57.0-412.4)	Female	39	46.0	84.8	(60.3-115.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	22.5	88.8	(54.2-137.1)	Female	52	53.5	97.2	(72.6-127.4)
Female	18	18.3	98.2	(58.2-155.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	809	797.4	101.5	(94.6-108.7)
Male	19	18.4	103.4	(62.2-161.5)	Female	827	833.4	99.2	(92.6-106.2)
Female	7	6.5	107.0	(42.8-220.4)					
<b><u>Lung and Bronchus</u></b>									
Male	104	105.3	98.7	(80.7-119.6)					
Female	140	115.5	121.2	(102.0-143.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Female</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	10.3	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	Female	5	5.6	88.6	(28.6-206.8)
<b><u>Leukemia</u></b>					<b><u>Male</u></b>				
Male	0	0.3	nc	(nc-nc)	<b><u>Female</u></b>				
Female	0	0.1	nc	(nc-nc)	<b><u>Male</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Female</u></b>				
Male	1	0.2	nc	(nc-nc)	<b><u>Male</u></b>				
Female	0	0.0	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>Male</u></b>				
Male	1	1.4	nc	(nc-nc)	<b><u>Female</u></b>				
Female	1	0.8	nc	(nc-nc)	<b><u>Male</u></b>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Male</u></b>				
Male	0	0.1	nc	(nc-nc)	9	8.7	103.7	(47.3-196.9)	
Female	0	0.0	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Leukemia</u></b>					8				
Male	0	0.2	nc	(nc-nc)	11.1	72.3	(31.1-142.5)		
Female	0	0.2	nc	(nc-nc)					
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	1	0.2	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	1.1	nc	(nc-nc)					
Female	0	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	28.7	38.4	(19.1-68.7)	Male	46	17.8	257.9	(188.8-344.0)
Female	10	10.8	92.2	(44.1-169.6)	Female	27	14.3	189.3	(124.7-275.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	5.0	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	13	15.8	82.4	(43.9-141.0)
Female	104	106.3	97.9	(80.0-118.6)	Female	24	13.9	172.9	(110.7-257.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.7	nc	(nc-nc)	Male	7	11.3	62.0	(24.8-127.7)
<b><u>Colon / Rectum</u></b>					Female	8	5.5	145.3	(62.6-286.4)
Male	28	32.7	85.7	(56.9-123.8)	<b><u>Ovary</u></b>				
Female	39	35.8	109.1	(77.6-149.1)	Female	11	9.9	111.3	(55.5-199.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	7.5	80.0	(29.2-174.2)	Male	6	9.2	64.9	(23.7-141.4)
Female	2	2.3	nc	(nc-nc)	Female	12	10.8	111.5	(57.5-194.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	114	107.9	105.7	(87.2-127.0)
Female	2	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	6.6	nc	(nc-nc)
Male	11	14.7	74.8	(37.3-133.9)	Female	1	4.3	nc	(nc-nc)
Female	13	8.9	146.5	(77.9-250.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.5	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	7	5.6	124.3	(49.8-256.2)
<b><u>Leukemia</u></b>					Female	25	17.4	144.0	(93.1-212.5)
Male	10	10.4	95.8	(45.9-176.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	8.2	109.6	(50.0-208.1)	Female	25	24.3	102.9	(66.6-152.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	8.4	59.8	(19.3-139.5)	Male	336	376.5	89.2	(79.9-99.3)
Female	1	3.1	nc	(nc-nc)	Female	402	376.5	106.8	(96.6-117.7)
<b><u>Lung and Bronchus</u></b>									
Male	35	51.8	67.5	(47.0-93.9)					
Female	48	54.6	87.8	(64.8-116.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	12	8.4	143.2	(73.9-250.1)	Female	2	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	0.7	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	9	10.0	90.0	(41.1-170.9)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.3	nc	(nc-nc)
Male	4	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.8	nc	(nc-nc)	Female	5	2.0	253.5	(81.7-591.5)
Female	1	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	41	32.8	125.1	(89.8-169.8)
Male	2	0.8	nc	(nc-nc)	Female	36	28.3	127.2	(89.1-176.1)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	9	4.2	214.9	(98.1-408.0)					
Female	7	4.0	172.9	(69.3-356.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	13.0	107.7	(58.8-180.7)	Male	5	8.6	57.9	(18.6-135.0)
Female	7	4.4	157.6	(63.1-324.7)	Female	20	6.4	311.6	(190.2-481.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.4	148.0	(73.8-264.9)
Female	54	46.8	115.3	(86.6-150.4)	Female	3	5.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	19	15.0	126.8	(76.3-198.1)	Female	6	4.3	139.9	(51.1-304.4)
Female	16	14.4	111.4	(63.7-181.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	4.3	116.6	(37.6-272.1)
Male	8	3.6	221.8	(95.5-437.0)	Female	5	4.4	114.6	(36.9-267.4)
Female	3	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	57	53.6	106.4	(80.5-137.8)
Male	4	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	5	3.0	165.7	(53.4-386.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.7	nc	(nc-nc)
Male	10	7.1	140.9	(67.4-259.1)	<b><u>Testis</u></b>				
Female	4	3.9	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	8	8.5	94.5	(40.7-186.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	4.7	nc	(nc-nc)	Female	12	10.8	111.1	(57.3-194.1)
Female	5	3.4	145.3	(46.8-339.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	210	180.2	116.5	(101.3-133.4)
Male	4	4.1	nc	(nc-nc)	Female	210	162.8	129.0	(112.2-147.7)
Female	1	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	28	24.6	114.0	(75.7-164.7)					
Female	43	23.7	181.4	(131.2-244.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	19.6	117.2	(74.3-175.9)	Male	16	12.7	125.7	(71.8-204.1)
Female	7	6.8	102.3	(41.0-210.7)	Female	7	10.0	70.1	(28.1-144.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	6	3.4	176.3	(64.4-383.7)
Female	8	3.1	255.7	(110.3-503.8)	Female	2	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	8	11.3	70.7	(30.4-139.2)
Female	66	73.7	89.6	(69.3-114.0)	Female	9	9.1	98.8	(45.1-187.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.7	nc	(nc-nc)	Male	13	8.0	161.9	(86.1-276.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	23.0	47.7	(23.8-85.4)	Female	11	6.7	163.7	(81.6-292.9)
Female	21	22.6	93.0	(57.6-142.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	6.4	110.1	(44.1-226.9)
Male	6	5.1	116.8	(42.6-254.2)	Female	4	6.7	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	70	73.2	95.7	(74.6-120.9)
Male	4	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.7	nc	(nc-nc)
Male	13	10.5	123.8	(65.9-211.8)	<b><u>Testis</u></b>				
Female	3	6.0	nc	(nc-nc)	Male	8	2.3	354.9	(152.8-699.3)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	11	13.3	82.9	(41.3-148.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	7.4	149.1	(74.3-266.7)	Female	15	16.8	89.0	(49.8-146.9)
Female	4	5.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	266	262.5	101.3	(89.5-114.3)
Male	8	5.9	134.5	(57.9-265.0)	Female	229	252.9	90.6	(79.2-103.1)
Female	4	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	33	35.8	92.3	(63.5-129.6)					
Female	23	35.5	64.8	(41.1-97.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	5	9.0	55.4	(17.9-129.4)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	2.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	11	10.2	107.9	(53.8-193.1)
Male	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.9	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	32	34.7	92.2	(63.0-130.1)
Male	0	0.8	nc	(nc-nc)	Female	25	29.0	86.2	(55.7-127.2)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	4	4.3	nc	(nc-nc)					
Female	2	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	14.2	77.7	(38.7-139.0)	Male	10	10.0	100.1	(47.9-184.0)
Female	5	4.4	114.3	(36.8-266.7)	Female	4	7.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.0	198.7	(72.6-432.6)	Male	2	2.6	nc	(nc-nc)
Female	5	2.3	219.0	(70.6-511.1)	Female	2	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	7	8.7	80.7	(32.3-166.2)
Female	65	55.0	118.1	(91.1-150.5)	Female	6	6.2	96.9	(35.4-210.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	6	6.8	88.5	(32.3-192.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	20	17.1	116.8	(71.3-180.4)	Female	3	4.9	nc	(nc-nc)
Female	13	14.4	90.4	(48.1-154.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	4.8	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	69	62.0	111.2	(86.5-140.7)
Male	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.7	nc	(nc-nc)
Male	7	8.5	82.1	(32.9-169.2)	<b><u>Testis</u></b>				
Female	3	4.3	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	15	10.6	141.0	(78.9-232.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	5.5	164.0	(74.8-311.4)	Female	18	12.7	141.6	(83.9-223.8)
Female	4	3.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	207	206.9	100.0	(86.9-114.6)
Male	7	4.9	142.1	(56.9-292.9)	Female	189	179.0	105.6	(91.1-121.8)
Female	3	1.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	15	27.2	55.1	(30.8-90.9)					
Female	23	24.0	95.9	(60.8-143.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	44.8	84.8	(60.0-116.4)	Male	19	27.8	68.5	(41.2-106.9)
Female	13	16.7	77.6	(41.3-132.7)	Female	17	23.0	74.0	(43.1-118.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	8.2	73.0	(26.7-158.9)	Male	5	7.5	66.7	(21.5-155.7)
Female	2	7.5	nc	(nc-nc)	Female	2	6.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	26	25.0	104.1	(68.0-152.6)
Female	151	157.9	95.6	(81.0-112.2)	Female	17	21.5	79.0	(46.0-126.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	11	6.0	184.3	(91.9-329.8)	Male	24	16.6	144.3	(92.4-214.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	50	51.2	97.7	(72.5-128.8)	Female	14	15.1	92.7	(50.7-155.6)
Female	53	55.7	95.1	(71.2-124.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	18	14.1	127.3	(75.4-201.2)
Male	8	11.0	73.0	(31.4-143.9)	Female	22	16.7	131.7	(82.5-199.4)
Female	5	3.5	144.5	(46.6-337.1)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	114	150.7	75.6	(62.4-90.9)
Male	3	3.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	3.2	nc	(nc-nc)	Male	5	10.2	49.0	(15.8-114.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	8	6.9	116.8	(50.3-230.1)
Male	17	22.0	77.2	(45.0-123.7)	<b><u>Testis</u></b>				
Female	8	13.4	59.7	(25.7-117.6)	Male	4	5.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	9	6.3	143.2	(65.3-271.8)	Male	7	9.0	78.2	(31.3-161.1)
Female	1	1.9	nc	(nc-nc)	Female	14	29.0	48.3	(26.4-81.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	16.8	89.5	(50.1-147.6)	Female	39	35.5	109.8	(78.0-150.0)
Female	9	13.3	67.8	(30.9-128.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	505	568.8	88.8	(81.2-96.9)
Male	21	12.5	168.3	(104.1-257.2)	Female	528	577.0	91.5	(83.9-99.7)
Female	6	4.6	129.2	(47.2-281.2)					
<b><u>Lung and Bronchus</u></b>									
Male	73	78.5	93.0	(72.9-116.9)					
Female	79	82.0	96.3	(76.3-120.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	5.4	185.6	(88.9-341.3)	Male	7	3.9	181.2	(72.6-373.3)
Female	1	2.5	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	28	26.0	107.7	(71.5-155.6)	Female	2	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	6.6	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	12	8.5	141.1	(72.8-246.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	1.8	nc	(nc-nc)
Male	3	1.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	23	21.8	105.3	(66.7-158.0)
Male	3	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.0	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	7	4.7	148.1	(59.3-305.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	2.1	nc	(nc-nc)	Female	5	5.8	86.8	(28.0-202.6)
Female	2	2.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	86	77.3	111.2	(89.0-137.4)
Male	2	1.9	nc	(nc-nc)	Female	81	91.0	89.1	(70.7-110.7)
Female	0	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	8	10.0	79.7	(34.3-157.1)					
Female	12	12.7	94.8	(48.9-165.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	11.0	63.7	(25.5-131.3)	Male	11	8.2	133.6	(66.6-239.1)
Female	4	3.6	nc	(nc-nc)	Female	10	6.8	146.7	(70.2-269.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	2.7	256.2	(102.7-528.0)	Male	0	2.1	nc	(nc-nc)
Female	5	2.1	232.8	(75.0-543.4)	Female	3	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.4	68.0	(21.9-158.6)
Female	62	49.8	124.6	(95.5-159.7)	Female	5	5.3	93.7	(30.2-218.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.1	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	10	14.4	69.7	(33.4-128.1)	Female	4	4.3	nc	(nc-nc)
Female	10	12.5	79.7	(38.2-146.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	3.8	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	50	47.5	105.3	(78.1-138.8)
Male	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.5	nc	(nc-nc)
Male	6	7.0	85.2	(31.1-185.4)	<b><u>Testis</u></b>				
Female	1	3.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	23	10.6	216.2	(137.0-324.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	4.8	126.0	(46.0-274.2)	Female	15	10.8	138.8	(77.6-228.9)
Female	2	3.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	138	165.8	83.2	(69.9-98.3)
Male	3	4.1	nc	(nc-nc)	Female	183	158.2	115.7	(99.5-133.7)
Female	2	1.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	10	20.4	49.1	(23.5-90.3)					
Female	17	19.5	87.2	(50.8-139.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	22	14.9	147.9	(92.7-224.0)	Female	1	1.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	6.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	7	3.6	191.9	(76.9-395.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	1.6	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	13	20.4	63.7	(33.9-108.9)
Male	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.4	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.9	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	47	71.1	66.1	(48.6-87.9)
Male	0	1.7	nc	(nc-nc)	Female	55	47.2	116.5	(87.8-151.7)
Female	0	0.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	9.3	64.8	(23.7-141.1)					
Female	5	5.8	85.8	(27.7-200.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	23.2	47.5	(23.7-85.0)	Male	11	15.0	73.1	(36.4-130.8)
Female	7	7.1	98.5	(39.5-202.9)	Female	9	10.8	83.4	(38.0-158.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.4	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	0	3.4	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	7	13.2	52.9	(21.2-109.0)
Female	83	78.8	105.4	(83.9-130.6)	Female	12	9.6	124.7	(64.4-217.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.0	165.1	(53.2-385.3)	Male	12	9.6	125.0	(64.5-218.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	27.2	88.1	(56.4-131.1)	Female	9	7.1	126.3	(57.6-239.8)
Female	21	23.0	91.3	(56.5-139.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	7.5	106.1	(45.7-209.1)
Male	7	6.1	114.3	(45.8-235.4)	Female	9	7.0	129.3	(59.0-245.5)
Female	2	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	93	88.3	105.3	(85.0-129.1)
Male	0	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	5	5.4	91.7	(29.6-214.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	2.7	nc	(nc-nc)
Male	8	12.3	65.0	(28.0-128.2)	<b><u>Testis</u></b>				
Female	9	6.5	139.4	(63.6-264.7)	Male	3	2.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	3.5	142.0	(45.8-331.3)	Male	3	5.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	19	14.8	128.4	(77.3-200.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	8.7	103.3	(47.1-196.1)	Female	24	18.1	132.6	(84.9-197.3)
Female	4	5.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	275	311.7	88.2	(78.1-99.3)
Male	6	7.0	85.5	(31.2-186.1)	Female	280	269.1	104.1	(92.2-117.0)
Female	1	2.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	37	41.5	89.2	(62.8-123.0)					
Female	39	38.5	101.2	(72.0-138.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	11.2	142.9	(81.6-232.1)	Male	11	8.0	137.5	(68.5-246.0)
Female	5	4.3	115.1	(37.1-268.6)	Female	8	6.8	117.2	(50.4-230.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	7	6.9	102.1	(40.9-210.5)
Female	59	51.6	114.4	(87.1-147.6)	Female	12	6.0	200.6	(103.5-350.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	5	5.5	91.0	(29.3-212.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	13.7	87.4	(45.1-152.6)	Female	4	4.6	nc	(nc-nc)
Female	16	14.0	114.6	(65.4-186.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	3.3	nc	(nc-nc)	Male	53	50.2	105.6	(79.1-138.1)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	6.8	117.7	(50.7-231.9)	Female	11	12.3	89.8	(44.7-160.6)
Female	5	4.1	122.0	(39.3-284.8)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	3.3	179.2	(65.4-390.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	7	4.1	171.5	(68.7-353.5)	Male	35	21.6	161.9	(112.8-225.2)
Female	1	1.3	nc	(nc-nc)	Female	31	23.9	129.5	(88.0-183.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	2.5	203.8	(65.7-475.6)	Male	1	1.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	11	8.4	130.4	(65.0-233.3)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	2.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	9	11.3	79.9	(36.5-151.8)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.3	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	0.9	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	37	35.9	103.0	(72.5-142.0)
Male	1	0.8	nc	(nc-nc)	Female	25	28.1	89.1	(57.6-131.5)
Female	1	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	5	4.8	104.0	(33.5-242.7)					
Female	3	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	17.2	110.8	(66.7-173.0)	Male	13	11.2	116.6	(62.0-199.4)
Female	5	6.5	76.9	(24.8-179.4)	Female	16	8.8	181.2	(103.5-294.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.1	195.1	(71.2-424.7)	Male	3	3.0	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	9	9.7	92.4	(42.2-175.4)
Female	79	66.1	119.5	(94.6-148.9)	Female	12	8.4	142.5	(73.6-249.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.3	nc	(nc-nc)	Male	10	7.3	137.6	(65.9-253.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	10	20.3	49.2	(23.6-90.6)	Female	11	6.1	180.3	(89.9-322.6)
Female	24	21.3	112.5	(72.0-167.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	5.6	88.7	(28.6-207.1)
Male	3	4.7	nc	(nc-nc)	Female	13	6.4	202.2	(107.5-345.7)
Female	1	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	78	68.0	114.7	(90.7-143.2)
Male	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	5	4.0	124.1	(40.0-289.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	2.6	nc	(nc-nc)
Male	8	9.2	86.5	(37.2-170.4)	<b><u>Testis</u></b>				
Female	3	5.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	6	3.7	161.9	(59.1-352.3)
Female	1	0.8	nc	(nc-nc)	Female	10	11.0	90.8	(43.5-167.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	6.2	144.2	(65.8-273.7)	Female	16	15.2	104.9	(59.9-170.4)
Female	7	4.9	143.6	(57.5-295.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	239	233.5	102.4	(89.8-116.2)
Male	4	5.4	nc	(nc-nc)	Female	258	230.7	111.8	(98.6-126.4)
Female	5	1.9	269.5	(86.8-628.9)					
<b><u>Lung and Bronchus</u></b>									
Male	27	31.6	85.5	(56.3-124.3)					
Female	22	33.4	66.0	(41.3-99.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	12.7	94.6	(48.8-165.2)	Male	11	8.4	130.5	(65.1-233.5)
Female	7	5.3	130.9	(52.4-269.6)	Female	10	7.5	133.4	(63.9-245.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.4	107.8	(46.4-212.5)
Female	65	54.2	120.0	(92.6-153.0)	Female	5	7.0	71.8	(23.1-167.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	8	5.5	145.4	(62.6-286.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	13	15.2	85.5	(45.5-146.2)	Female	3	5.0	nc	(nc-nc)
Female	23	17.8	129.1	(81.8-193.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	2	3.4	nc	(nc-nc)	9	4.2	215.2	(98.2-408.6)	
Female	1	1.1	nc	(nc-nc)	Female				
<b><u>Hodgkin Lymphoma</u></b>					7				
Male	0	1.0	nc	(nc-nc)	5.3				
Female	0	0.9	nc	(nc-nc)	131.8				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Prostate</u></b>				
Male	6	7.0	86.3	(31.5-187.7)	Male	58	49.5	117.1	(88.9-151.4)
Female	6	4.5	134.6	(49.2-293.1)	<b><u>Stomach</u></b>				
<b><u>Larynx</u></b>					Male				
Male	1	2.0	nc	(nc-nc)	6	3.0	199.1	(72.7-433.4)	
Female	0	0.6	nc	(nc-nc)	Female				
<b><u>Leukemia</u></b>					2				
Male	7	4.9	143.9	(57.6-296.5)	2.2				
Female	8	4.2	190.9	(82.2-376.3)	nc				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Testis</u></b>				
Male	1	4.0	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	28	23.0	121.5	(80.7-175.6)	2	2.9	nc	(nc-nc)	
Female	17	26.8	63.4	(36.9-101.5)	Female				
					13				
					9.7				
					134.3				
					(71.4-229.6)				
					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
					Female				
					15				
					12.1				
					123.7				
					(69.2-204.1)				
					<b><u>All Sites / Types</u></b>				
					Male				
					191				
					174.0				
					109.8				
					(94.8-126.5)				
					Female				
					206				
					190.5				
					108.1				
					(93.9-123.9)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	9.2	129.9	(67.0-226.9)	Male	5	6.8	73.6	(23.7-171.8)
Female	4	3.8	nc	(nc-nc)	Female	4	5.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	6.0	100.4	(36.6-218.4)
Female	50	43.3	115.5	(85.7-152.3)	Female	5	5.2	96.6	(31.1-225.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	5	4.7	107.1	(34.5-250.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	11.6	206.3	(132.1-306.9)	Female	3	3.9	nc	(nc-nc)
Female	12	12.7	94.6	(48.8-165.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	3.1	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	8	3.7	213.3	(91.9-420.4)
Female	0	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	46	39.0	118.0	(86.4-157.4)
Male	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	6	2.3	264.0	(96.4-574.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.5	nc	(nc-nc)
Male	6	5.7	104.4	(38.1-227.2)	<b><u>Testis</u></b>				
Female	5	3.4	145.6	(46.9-339.8)	Male	3	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	7	8.2	85.3	(34.2-175.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	3.8	nc	(nc-nc)	Female	10	9.8	102.4	(49.0-188.3)
Female	3	3.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	160	136.4	117.3	(99.8-136.9)
Male	2	3.4	nc	(nc-nc)	Female	148	145.9	101.4	(85.7-119.1)
Female	1	1.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	17.3	109.5	(65.9-171.1)					
Female	21	19.8	105.9	(65.5-161.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	4.9	264.9	(140.9-452.9)	Male	3	4.1	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.6	167.6	(61.2-364.9)
Female	23	25.6	89.9	(57.0-134.9)	Female	2	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	6.7	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Female	6	7.8	77.3	(28.2-168.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	1.7	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	5	2.3	216.2	(69.7-504.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	40	23.2	172.7	(123.4-235.2)
Male	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.9	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	5	2.1	242.2	(78.0-565.1)	Male	1	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.2	nc	(nc-nc)	Female	7	5.8	119.9	(48.0-247.1)
Female	5	1.9	267.7	(86.3-624.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	101	80.0	126.2	(102.8-153.3)
Male	1	2.0	nc	(nc-nc)	Female	87	87.9	99.0	(79.3-122.1)
Female	1	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	13	9.5	136.4	(72.6-233.3)					
Female	13	12.1	107.1	(57.0-183.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	14	13.4	104.3	(57.0-175.0)	Female	2	1.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	4.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	1.1	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	19	14.7	129.6	(78.0-202.3)
Male	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.5	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.3	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	52	48.3	107.7	(80.4-141.2)
Male	0	1.1	nc	(nc-nc)	Female	44	45.2	97.4	(70.8-130.8)
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	7	6.3	111.4	(44.6-229.4)					
Female	5	6.3	78.9	(25.4-184.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	46.7	115.5	(86.8-150.7)	Male	13	34.0	38.2	(20.3-65.3)
Female	15	20.7	72.4	(40.5-119.5)	Female	12	35.4	33.9	(17.5-59.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	11.7	93.6	(46.7-167.6)	Male	12	8.4	143.0	(73.8-249.8)
Female	8	11.8	67.8	(29.2-133.5)	Female	10	8.0	125.1	(59.9-230.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	29	30.5	95.0	(63.6-136.4)
Female	175	234.4	74.7	(64.0-86.6)	Female	24	29.0	82.7	(53.0-123.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	16	10.3	155.2	(88.7-252.1)	Male	25	22.2	112.4	(72.7-165.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	61	58.7	103.9	(79.5-133.5)	Female	12	21.6	55.4	(28.6-96.8)
Female	72	69.5	103.6	(81.1-130.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	12	12.9	93.1	(48.1-162.6)	Male	18	15.5	115.9	(68.7-183.2)
Female	6	4.3	139.5	(50.9-303.6)	Female	21	20.4	102.9	(63.6-157.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	2	5.9	nc	(nc-nc)	Male	24	11.5	209.0	(133.8-310.9)
Female	7	5.9	119.5	(47.9-246.3)	Female	8	8.3	96.0	(41.4-189.3)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	20	28.0	71.5	(43.7-110.5)	Male	8	10.3	77.3	(33.3-152.4)
Female	13	19.0	68.3	(36.3-116.8)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	7.5	160.9	(83.0-281.0)	Female	42	52.1	80.5	(58.0-108.9)
Female	4	2.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	19	20.5	92.6	(55.7-144.6)	Male	730	674.8	108.2	(100.5-116.3)
Female	20	18.9	106.0	(64.7-163.8)	Female	686	813.5	84.3	(78.1-90.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	28	15.7	178.2	(118.4-257.6)	<b><u>All Sites / Types</u></b>				
Female	10	6.2	160.9	(77.0-296.0)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	90	84.4	106.6	(85.7-131.0)	<b><u>All Sites / Types</u></b>				
Female	86	107.3	80.2	(64.1-99.0)	<b><u>All Sites / Types</u></b>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	6.6	151.9	(72.7-279.4)	Male	7	4.6	153.7	(61.6-316.8)
Female	1	2.9	nc	(nc-nc)	Female	9	3.9	233.4	(106.5-443.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.9	128.6	(41.4-300.2)
Female	23	28.3	81.2	(51.5-121.9)	Female	5	3.7	135.0	(43.5-315.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	7.8	114.7	(52.3-217.7)	Female	0	2.6	nc	(nc-nc)
Female	12	9.3	128.6	(66.4-224.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	4	1.9	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	33	28.5	115.6	(79.6-162.4)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	3	3.8	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	1	2.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	7	4.8	146.7	(58.8-302.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.3	nc	(nc-nc)	Female	1	6.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	20	12.8	156.4	(95.5-241.5)	Male	112	94.6	118.4	(97.5-142.5)
Female	16	14.8	108.1	(61.7-175.5)	Female	94	100.5	93.6	(75.6-114.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	12.1	83.0	(39.7-152.6)	Male	7	7.9	88.3	(35.4-182.0)
Female	2	4.0	nc	(nc-nc)	Female	7	6.1	115.5	(46.3-238.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.0	nc	(nc-nc)
Female	57	43.3	131.8	(99.8-170.7)	Female	2	5.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.7	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	14.4	83.3	(43.0-145.5)	Female	2	4.0	nc	(nc-nc)
Female	13	13.1	99.0	(52.7-169.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	3.9	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	6	3.9	152.8	(55.8-332.5)
Female	0	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	37	44.7	82.7	(58.2-114.0)
Male	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.6	nc	(nc-nc)
Male	8	6.4	124.2	(53.5-244.8)	<b><u>Testis</u></b>				
Female	3	3.5	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	8.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	4.6	130.1	(47.5-283.2)	Female	12	9.8	122.1	(63.0-213.4)
Female	3	3.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	145	161.9	89.5	(75.6-105.4)
Male	5	3.8	132.1	(42.6-308.2)	Female	159	149.2	106.6	(90.6-124.5)
Female	0	1.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	31	21.4	144.6	(98.2-205.3)					
Female	32	20.9	153.2	(104.7-216.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	8.9	157.9	(86.3-265.0)	Male	9	5.0	180.6	(82.4-342.9)
Female	1	3.9	nc	(nc-nc)	Female	7	4.3	164.7	(66.0-339.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	36	31.1	115.6	(81.0-160.1)	Female	2	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	0.9	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	18	9.6	187.0	(110.8-295.5)	Female	3	3.1	nc	(nc-nc)
Female	12	12.9	93.0	(48.0-162.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	2	2.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	38	29.2	130.1	(92.1-178.6)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	3	3.9	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	6	3.1	195.5	(71.4-425.5)	Male	1	1.4	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	6	4.3	141.0	(51.5-306.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	2.3	nc	(nc-nc)	Female	10	7.1	141.6	(67.8-260.4)
Female	3	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	13	15.3	85.0	(45.2-145.3)	Male	119	106.9	111.3	(92.2-133.2)
Female	11	17.9	61.5	(30.7-110.1)	Female	116	118.9	97.5	(80.6-117.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	41	46.8	87.6	(62.9-118.9)	Male	23	30.1	76.5	(48.5-114.8)
Female	20	16.2	123.4	(75.3-190.5)	Female	20	23.8	84.1	(51.3-129.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	8.9	112.3	(53.8-206.5)	Male	8	8.0	100.6	(43.3-198.1)
Female	5	7.5	67.0	(21.6-156.4)	Female	3	6.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	26	26.8	97.1	(63.4-142.3)
Female	171	167.9	101.8	(87.2-118.3)	Female	25	21.5	116.5	(75.4-172.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.5	92.0	(33.6-200.2)	Male	12	18.6	64.5	(33.3-112.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	41	54.4	75.4	(54.1-102.3)	Female	20	15.5	128.7	(78.6-198.7)
Female	54	53.6	100.8	(75.7-131.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	15.0	80.0	(41.3-139.7)
Male	10	12.0	83.3	(39.9-153.1)	Female	17	16.0	106.0	(61.7-169.8)
Female	2	3.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	139	169.4	82.1	(69.0-96.9)
Male	3	3.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	3.2	155.7	(50.2-363.3)	Male	7	10.9	64.4	(25.8-132.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	9	6.5	139.2	(63.5-264.3)
Male	19	24.3	78.1	(47.0-122.0)	<b><u>Testis</u></b>				
Female	13	13.8	93.9	(49.9-160.5)	Male	3	6.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	9	6.9	129.9	(59.3-246.7)	Male	4	10.1	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	26	31.8	81.7	(53.4-119.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	17.7	113.1	(69.1-174.7)	Female	40	37.9	105.5	(75.4-143.6)
Female	12	12.8	93.6	(48.3-163.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	521	616.9	84.5	(77.4-92.0)
Male	5	13.7	36.4	(11.7-85.0)	Female	569	589.5	96.5	(88.7-104.8)
Female	3	4.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	89	83.6	106.4	(85.4-130.9)					
Female	70	82.9	84.4	(65.8-106.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;